In The News
A research team supported in part by SU2C has published findings that show how we may be able to kill cancerous cells more effectively by combining drugs that work together to significantly disrupt a cancer cell’s ability to survive DNA damage. These findings are the first to show this combination drug therapy as a novel approach for treating acute myeloid leukemia (AML) and potentially, many other cancers.
SU2C supported clinical trial shows promise with immunotherapy and lung cancer
Q&A with SU2C scientist on stem cells and brain cancer
Employees of Bristol-Myers Squibb are riding to support SU2C cancer research
Ten new scientists join SU2C to achieve high-risk, high-reward projects